Stocktoria
PROKIDNEY CORP. PROK
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-06-30
PROKIDNEY CORP. financials (annual)
Bars are annual figures from 2021 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $893,000 | $76,000 | $0 | $0 | — |
| R&D expense | $114.1M | $127.7M | $106.7M | $82.1M | $46.3M |
| Operating income | -$165.0M | -$183.7M | -$151.5M | -$153.0M | -$55.1M |
| Interest expense | $4,000 | $9,000 | $12,000 | $215,000 | $0 |
| Income tax | $414,000 | -$598,000 | $6.0M | $896,000 | $38,000 |
| Net income | -$69.0M | -$61.2M | -$35.5M | — | -$55.1M |
| EPS (diluted) | — | — | — | $-0.23 | — |
| Operating cash flow | -$120.1M | -$126.4M | -$90.1M | -$77.1M | -$50.3M |
| Free cash flow | -$135.3M | -$155.9M | -$124.3M | -$78.9M | -$55.5M |
| Cash & equivalents | $108.5M | $99.1M | $60.6M | $490.3M | $20.6M |
| Total assets | $335.6M | $441.1M | $420.6M | $518.0M | $40.3M |
| Total liabilities | $34.8M | $39.4M | $29.2M | $13.1M | $13.4M |
| Shareholders' equity | -$1.0B | -$995.0M | -$1.1B | -$1.1B | $26.9M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue growth | +1075.0% | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.